Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Hannah FluhrerGeorg C HuttererSylvia GolbeckMichael StidlTobias NiedristRenate PichlerJohannes MischingerMaximilian SelesSebastian MannweilerJasmin SpiegelbergThomas BauernhoferPhilipp J JostSascha AhyaiRichard ZigeunerMartin PichlerDominik Andreas BarthPublished in: Therapeutic advances in medical oncology (2022)
Significant advances in the systemic medical treatment of mRCC during the recent decade and the introduction of immunotherapy exerted a major impact on patient outcomes in terms of OS in a real-life population.